Is This BioTech in JNJ's Sights?

Dear National Review Reader, Below you will find a special message from one of our sponsoring advertisers, Advantage Media Group. As you know, investing in over-the-counter stocks carries a lot of risk, but the rewards can be exceptional. And although National Review hasn't researched and cannot assess the following information, we do hope it will act as a useful tool when exploring your investment options. National Review always recommends you conduct your own due diligence before entering into any type of financial investment. National Review, Inc. Arch Therapeutics (ARTH) announces stunning medical breakthrough! May be the most wide-reaching medical discovery in decades! This could completely change current procedures in surgery, first response, even your child's scraped knee! Arch Therapeutics (ARTH) stands a few key steps from release of AC5™, a new product that could revolutionize how bleeding is controlled. News of AC5™ could rapidly spread worldwide, triggering a potential boom in ARTH shares this year! ARTH is an immediate buy! Fellow Investor: Bleeding complications have been a serious issue in surgery, often resulting in life-threatening situations for surgeons, doctors and patients. Outside the surgery, controlling blood loss is key in trauma response, especially in the military where blood loss is the number one battlefield cause of death. Even routine bleeding from scrapes and cuts can be stopped, which could render the 100-year-old bandage obsolete. Clearly, this medical breakthrough could be worth a fortune for ARTH shareholders, especially if you get in now. Arch Therapeutics is moving AC5™ into final phases to market. I strongly recommend ARTH as an immediate buy. This may be your last chance to catch ARTH early. If you get excited about the chance to catch a breakout early, read my new online Arch Therapeutics report right now. It reveals how: Pre-clinical trials confirmed its efficacy with stunning results... Arch Therapeutics gained exclusive licenses to the product from the Massachusetts Institute of Technology...... It is now entering human trials to regulatory approval, which is the pivotal point for ground floor investing... Surgeons are already calling this the "Holy Grail" that could be used in "80% of cases"... A stellar team of world-renown medical researchers, surgeons and medical products specialists are preparing to bring this product to market... Its European introduction should accelerate regulatory approvals to explosive growth in America... And most important for shareholders... This is the point when ARTH can light up radar screens for biotech investors! But with final phases of product trials and approvals underway, this won't last long! Don't expect that to last. Though you may still buy ARTH around a dollar, news of Arch Therapeutics could propel ARTH into the $3.00 to $5.00 range this year! Arch Therapeutics is one of the best medical technology stocks I've discovered in my career. The product is a real breakthrough, its uses are global, and the profit potential for shareholders is stunning. Get all the details on this emerging story through my new report. I urge you to read it now! Yours for Profit, Ian Cooper, Publisher Speed Retirement System Newsletter View Important Disclaimer Here Manage your National Review subscriptions. We respect your right to privacy. View our policy. This email was sent by: National Review, Inc. 215 Lexington Avenue, 11th Floor New York, NY 10016 1379